Search for content, post, videos

QureTech Bio appoints new CEO

Helén Fält Photo Ola Jacobsen

QureTech Bio has appointed Helén Fält as its new acting CEO, replacing Fredrik Almqvist, one of the company’s original founders.

“We have recently secured significant new investment and so it feels like the perfect time for Helén to come in and develop our business even further,” says Fredrik Almqvist.

Venture capital company Nascent Invest recently bought shares of QureTech Bio as part of a targeted share issue. The multi-million SEK investment will provide long-term security for the Swedish life science company as it continues its work to discover new solutions to combat antibiotic-resistant bacteria. A combined total of SEK 14.4 million has been invested in the company by Nascent Invest together with existing shareholders such as founders and Nordiska Centrumhus. The company’s incoming CEO Helén Fält, who previously worked as QureTech Bio’s business coach at Umeå Biotech Incubator (UBI), will now be responsible for driving development forwards.

Helén Fält

Helén Fält has previously worked within life science research and development as well as pharmaceutical contract manufacturing, and has also participated in clinical studies in the Västerbotten region.

“I have worked in this industry throughout my entire professional life in various organisations and positions. I have a background in research, which means that I know what is needed for the company to succeed , but also that I understand the conditions that founders, owners and employees have,” says Helén Fält. “At UBI I have worked with all phases in the development of startups. In recent years I have worked intensely with financing and growth, participated as an adjunct board member in several startups and established a wide network of contacts. I enjoy working in teams and towards common goals, and hope to contribute with my knowledge, positive attitude and drive. I look forward to this challenge and hope to grow into the role and develop professionally together with the company.”

“The US is a key market for us, so we are at a very exciting stage.”

“QureTech Bio recently received preliminary approval in the US for a patent application for one of our drug candidates. We hope this can be used to treat tuberculosis in the future. The US is a key market for us, so we are at a very exciting stage,” says Helén Fält.

Photo of Helén Fält: Ola Jacobsen